ARKG Performance — ARK Genomic Revolution ETF
Data updated: 2026-10-06
ARKG returned +33.35% year to date and +61.72% over one year to Jul 2026. Annualised returns are +0.57% over 3 years and −14.37% over 5 years. Against its Health Care Equity category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $102, against $137 for the category, and to $162 over one year, against $137. Volatility over the past three years was 41.71% a year. In the 12 months to Jul 2026 the fund lost a net $1.7M, and assets reached $1.56B.
ARKG Growth of $100
What $100 invested in ARK Genomic Revolution ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | ARKG | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $162 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $102 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $46 | $121 |
| Since data start (Feb 2020 – Jul 2026) | $120 | $167 |
ARKG Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +33.35% |
| 1 year | +61.72% |
| 3 years (annualised) | +0.57% |
| 5 years (annualised) | −14.37% |
ARKG Annual Returns
Calendar-year total returns of ARK Genomic Revolution ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +33.35% |
| 2025 | +22.72% |
| 2024 | −28.09% |
| 2023 | +16.24% |
| 2022 | −53.94% |
| 2021 | −33.90% |
| 2020 (Feb–Dec) | +187.31% |
ARKG Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.1% | −1.5% | −11.7% | +13.0% | +15.8% | +21.6% | −8.3% | — | — | — | — | — |
| 2025 | +13.9% | −8.4% | −15.6% | +6.0% | −4.9% | +16.2% | −1.9% | +3.6% | +12.4% | +12.0% | +0.1% | −7.1% |
| 2024 | −13.1% | +10.7% | −8.7% | −19.1% | +5.5% | −4.1% | +14.5% | −2.0% | −3.0% | −9.6% | +12.1% | −9.2% |
| 2023 | +19.4% | −9.6% | −1.3% | −3.6% | +9.3% | +7.8% | +11.2% | −15.0% | −13.7% | −17.3% | +20.4% | +18.3% |
| 2022 | −18.9% | −2.7% | −4.9% | −26.2% | −4.9% | −2.4% | +16.3% | −3.1% | −7.7% | +3.0% | −3.6% | −13.4% |
| 2021 | +9.3% | −8.2% | −5.4% | +0.4% | −8.1% | +13.3% | −8.8% | +1.6% | −12.9% | +0.6% | −15.5% | −2.9% |
| 2020 | — | +5.2% | −8.9% | +29.5% | +13.9% | +12.6% | +3.0% | +15.2% | +2.9% | +3.0% | +24.3% | +15.3% |
ARKG Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 41.71%
- 3-year Sharpe ratio: -0.09 (vs 4.5% risk-free rate)
- Best month: +21.56% (Jun 2026)
- Worst month: −19.13% (Apr 2024)
ARKG Fund Flows
Monthly money in and out of ARK Genomic Revolution ETF, from SEC Form N-PORT.
- 12-month net flow: −$1.7M
- 12-month gross sales (incl. reinvestments): $2.1B
- Sales ÷ redemptions: 1.00×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $216.3M | $248.5M | −$32.2M |
| Jun 2026 | $320.2M | $184.4M | $135.8M |
| May 2026 | $73.4M | $180.4M | −$107.0M |
| Apr 2026 | $233.2M | $173.7M | $59.5M |
| Mar 2026 | $71.5M | $184.2M | −$112.7M |
| Feb 2026 | $266.9M | $227.1M | $39.8M |
| Jan 2026 | $198.2M | $145.7M | $52.5M |
| Dec 2025 | $187.3M | $178.2M | $9.1M |
| Nov 2025 | $126.5M | $182.9M | −$56.4M |
| Oct 2025 | $293.6M | $199.0M | $94.6M |
| Sep 2025 | $56.4M | $120.7M | −$64.3M |
| Aug 2025 | $46.8M | $67.3M | −$20.5M |
ARKG Assets Under Management
Net assets of ARK Genomic Revolution ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $1.56B |
| 2026-04-30 | $1.24B |
| 2026-01-30 | $1.27B |
| 2025-10-31 | $1.31B |
| 2025-07-31 | $1.01B |
| 2025-04-30 | $953.88M |
| 2025-01-31 | $1.18B |
| 2024-10-31 | $1.18B |
| 2024-07-31 | $1.46B |
| 2024-04-30 | $1.31B |
| 2024-01-31 | $1.66B |
| 2023-10-31 | $1.43B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.